AstraZeneca's global biologics research and development arm, MedImmune, has completed its acquisition of Amplimmune, in a deal worth up to US $500 million. Amplimmune is a US-based biologics ...
When AstraZeneca acquired MedImmune in 2007 for $15 billion, some analysts felt the firm overpaid for the biotech company. This week, MedImmune celebrates its 25th anniversary – and has come to ...
The Minnesota Department of Health has reported two variant H3N2 (H3N2v) flu infections, both involving young people who ...
The phase IIIA trials randomized 792 patients ages 12 and older with severe asthma in a 2:1 ratio to depemokimab (100 mg ...
MedImmune, the global biologics research and development arm of AstraZeneca, and The University of Manchester have entered into a new research collaboration to generate cutting-edge protein ...
Dr. Steve Caffé is an accomplished industry executive with over 25 years of expertise in global product development and ...